Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Beam Therapeutics' Other Accumulated Expenses rose 528.16% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 528.16%. This contributed to the annual value of $7.8 million for FY2024, which is 7272.79% down from last year.
  • Per Beam Therapeutics' latest filing, its Other Accumulated Expenses stood at $2.7 million for Q3 2025, which was up 528.16% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Other Accumulated Expenses ranged from a high of $28.6 million in Q4 2023 and a low of $2.2 million during Q2 2025
  • For the 5-year period, Beam Therapeutics' Other Accumulated Expenses averaged around $9.9 million, with its median value being $7.2 million (2021).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 21294.87% in 2024, then tumbled by 9049.28% in 2025.
  • Beam Therapeutics' Other Accumulated Expenses (Quarter) stood at $7.0 million in 2021, then surged by 76.08% to $12.3 million in 2022, then skyrocketed by 133.58% to $28.6 million in 2023, then tumbled by 72.73% to $7.8 million in 2024, then plummeted by 65.29% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.2 million for Q2 2025, and $3.4 million during Q1 2025.